This study used 3 separate piecewise exponential survival models estimated for each solid organ the overall, demographic‐specific, and donation service area‐specific differences in the hazard of waitlist mortality before and after the national emergency declaration on March 13, 2020. Kidney waiting list mortality was higher after than before the national emergency (adjusted hazard ratio [aHR], 1.37; 95% CI, 1.23–1.52). The hazard of waitlist mortality was not significantly different before and after COVID‐19 for liver (aHR, 0.94), pancreas (aHR, 1.01), lung (aHR, 1.00), and heart (aHR, 0.94). Kidney candidates had notable variability in differences across donation service areas (aHRs, New York City, 2.52; New Jersey, 1.84; and Michigan, 1.56). The only demographic group with increased waiting list mortality were Blacks versus Whites (aHR, 1.41; 95% CI, 1.07–1.86) for kidney candidates.

20 acutely infected, 20 convalescent and 14 mRNA vaccinated patients were studied for neutralizing activities to 4 SARS-CoV-2 mutations. This study found neutralizing activity of infection- and vaccine-elicited antibodies against four SARS-CoV-2variants, including B.1, B.1.1.7, and N501Y. Because neutralization studies measure the ability of antibodies to block virus infection, these results suggest that infection- and vaccine induced immunity may be retained against the B.1.1.7 variant.

This study analyzed people who tested positive for the coronavirus during one or both of Denmark’s two surges of infection — from March to May and from September to December — in 2020. At about 6 months after initial infection, protection against repeat infection was approximately 80%, with no significant difference in reinfection rates between men and women. But this protection was reduced to 47% for those aged 65 years or older, emphasizing the need to prioritize vaccinations for this group.